Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Mexico: a systematic review. [PDF]
Ceballos Ruiz C, Navarro A.
europepmc +1 more source
Reigniting the institutional engine for pharmaceutical access: when policy experiments become new global evidence. [PDF]
Chen J, Li W.
europepmc +1 more source
From system building to global engagement: Current significance of and future directions for rare disease research in China. [PDF]
Tang W.
europepmc +1 more source
Navigating barriers to real-world evidence utilization for drug regulatory affairs and market access in Saudi Arabia. [PDF]
Sukkarieh HH +6 more
europepmc +1 more source
Real-world evidence and the future of personalized medicine: a global perspective on data, ethics, and equity. [PDF]
Sagkriotis A.
europepmc +1 more source
Utilization of real-world evidence in regulatory approvals for multiple myeloma therapies. [PDF]
Taylor L, Chen A, Pierre A.
europepmc +1 more source
Innovating HTA: a call for capacity building and standardization. [PDF]
Delnoij DMJ +6 more
europepmc +1 more source
Real-world evidence in metabolic dysfunction-associated steatotic liver disease (MASLD): insights, challenges, and future directions. [PDF]
Huang HT, Hewitt M, Li W, Alazawi W.
europepmc +1 more source
Diverging regulatory DNA in adaptive medical AI: US agility and EU accountability in lifecycle governance. [PDF]
Lee JH +6 more
europepmc +1 more source
Shaping the Future of Evidence Generation: Real-World Data to Drive Healthcare Transformation and Patient-Centered Decisions. [PDF]
Medina J +10 more
europepmc +1 more source

